Zobrazeno 1 - 10
of 194
pro vyhledávání: '"Zhengfei, Zhu"'
Autor:
Jianjiao Ni, Xiaofei Wang, Lin Wu, Xinghao Ai, Qian Chu, Chengbo Han, Xiaorong Dong, Yue Zhou, Yechun Pang, Zhengfei Zhu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-14 (2024)
Abstract This single-arm, multicenter, phase 2 trial (NCT04106180) investigated the triple combination of sintilimab (anti-PD1 antibody), stereotactic body radiotherapy (SBRT) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in metastati
Externí odkaz:
https://doaj.org/article/b6128d49dd7d4eeca87f7d7e659fb97b
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-7 (2024)
Abstract Background Small cell lung cancer (SCLC) is highly invasive with poor prognosis, and its treatment has historically been hindered due to the absence of targetable driver genomic alterations. However, the high genomic instability and replicat
Externí odkaz:
https://doaj.org/article/1593ff67ae544623ac0394fbf84586fc
Autor:
Hong Zhu, Yi Xu, Huiquan Gao, Xingwen Fan, Ming Fan, Kuaile Zhao, Huanjun Yang, Zhengfei Zhu, Kailiang Wu
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Background There was limited research data on large‐scale locally advanced non‐small cell lung cancer (LA‐NSCLC) radical radiotherapy (RT) reported in China. This study examined overall survival (OS), progression‐free survival (PFS),
Externí odkaz:
https://doaj.org/article/7c223d54176e456290031811585c0b86
Publikováno v:
Advances in Radiation Oncology, Vol 9, Iss 8, Pp 101549- (2024)
Purpose: Exosomes have been shown to play a role in most, if not all, steps of cancer progression. We still lack a comprehensive understanding of the bidirectional communication of exosomes between tumor cells and immune cells. This article aims to e
Externí odkaz:
https://doaj.org/article/0caf35d00f2d46b9aee7a54b5c66d266
Autor:
Tiantian Guo, Yue Zhou, Fei Liang, Zezhou Wang, Vincent Bourbonne, Lukas Käsmann, Nora Sundahl, Abraham Jing‐Ching Wu, Jianjiao Ni, Zhengfei Zhu
Publikováno v:
Cancer Communications, Vol 44, Iss 2, Pp 278-281 (2024)
Externí odkaz:
https://doaj.org/article/fdb09559a1de4c54b04716b5ce9cb384
Autor:
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wenzhao Zhong, Chengzhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Duan, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Chengbo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si‐Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tangfeng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wenxian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chunwei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tongmei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Publikováno v:
Thoracic Cancer, Vol 15, Iss 5, Pp 419-426 (2024)
Abstract Immune checkpoint inhibitor (ICI) rechallenge in non‐small cell lung cancer (NSCLC) is a promising therapeutic strategy. The situation for ICI rechallenge can be divided into three categories: adverse events (AEs); resistance to ICIs, and
Externí odkaz:
https://doaj.org/article/5593cfcf22cf4de189ad661dbe843899
Autor:
Lu Yu, Zhen Zhang, HeQing Yi, Jin Wang, Junyi Li, Xiaofeng Wang, Hui Bai, Hong Ge, Xiaoli Zheng, Jianjiao Ni, Haoran Qi, Yong Guan, Wengui Xu, Zhengfei Zhu, Ligang Xing, Andre Dekker, Leonard Wee, Alberto Traverso, Zhaoxiang Ye, Zhiyong Yuan
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-11 (2024)
Abstract Objectives Stereotactic body radiotherapy (SBRT) is a treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are unfit for surgery. Some patients may experience distant metastasis. This study aimed to develop a
Externí odkaz:
https://doaj.org/article/b3e696f352594251a7623527ef97baa7
Autor:
Chunwei Xu, Qian Wang, Dong Wang, Wenxian Wang, Wenfeng Fang, Ziming Li, Aijun Liu, Jinpu Yu, Wenzhao Zhong, Zhijie Wang, Yongchang Zhang, Jingjing Liu, Shirong Zhang, Xiuyu Cai, Anwen Liu, Wen Li, Ping Zhan, Hongbing Liu, Tangfeng Lv, Liyun Miao, Lingfeng Min, Yu Chen, Jingping Yuan, Feng Wang, Zhansheng Jiang, Gen Lin, Long Huang, Xingxiang Pu, Rongbo Lin, Weifeng Liu, Chuangzhou Rao, Dongqing Lv, Zongyang Yu, Xiaoyan Li, Chuanhao Tang, Chengzhi Zhou, Junping Zhang, Junli Xue, Hui Guo, Qian Chu, Rui Meng, Jingxun Wu, Rui Zhang, Jin Zhou, Zhengfei Zhu, Yongheng Li, Hong Qiu, Fan Xia, Yuanyuan Lu, Xiaofeng Chen, Rui Ge, Enyong Dai, Yu Han, Weiwei Pan, Fei Pang, Qingqing He, Jintao Huang, Kai Wang, Fan Wu, Bingwei Xu, Liping Wang, Youcai Zhu, Li Lin, Yanru Xie, Xinqing Lin, Jing Cai, Ling Xu, Jisheng Li, Xiaodong Jiao, Kainan Li, Jia Wei, Huijing Feng, Lin Wang, Yingying Du, Wang Yao, Xuefei Shi, Xiaomin Niu, Dongmei Yuan, Yanwen Yao, Jianhui Huang, Yue Feng, Yinbin Zhang, Pingli Sun, Hong Wang, Mingxiang Ye, Zhaofeng Wang, Yue Hao, Zhen Wang, Bin Wan, Donglai Lv, Shengjie Yang, Jin Kang, Jiatao Zhang, Chao Zhang, Juanjuan Ou, Lin Shi, Yina Wang, Bihui Li, Zhang Zhang, Zhongwu Li, Zhefeng Liu, Nong Yang, Lin Wu, Huijuan Wang, Gu Jin, Guansong Wang, Jiandong Wang, Meiyu Fang, Yong Fang, Yuan Li, Xiaojia Wang, Yiping Zhang, Xixu Zhu, Yi Shen, Shenglin Ma, Biyun Wang, Lu Si, Yong Song, Yuanzhi Lu, Jing Chen, Zhengbo Song
Publikováno v:
Global Medical Genetics, Vol 11, Iss 01, Pp 086-099 (2024)
The fusion genes NRG1 and NRG2, members of the epidermal growth factor (EGF) receptor family, have emerged as key drivers in cancer. Upon fusion, NRG1 retains its EGF-like active domain, binds to the ERBB ligand family, and triggers intracellular sig
Externí odkaz:
https://doaj.org/article/9709bead602f46d78dbb13fcba8fc177
Autor:
David J.H. Bian, Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Zhimin Zeng, Zhengfei Zhu, Ugur Sener, Rachna Malani, Yu Jung Kim, Eiki Ichihara, Victor Cohen, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner
Publikováno v:
Heliyon, Vol 10, Iss 9, Pp e29668- (2024)
Purpose: Leptomeningeal metastasis (LM) is a severe complication of non-small cell lung cancer (NSCLC). In patients with NSCLC LM harboring epidermal growth factor receptor (EGFR) mutations, osimertinib is favored over alternative EGFR tyrosine kinas
Externí odkaz:
https://doaj.org/article/47982575b8604d17a509444a6786dbf3
Autor:
Jianchun Duan, Wenfeng Fang, Hairong Xu, Jinliang Wang, Yuan Chen, Yi Ding, Xiaorong Dong, Yun Fan, Beili Gao, Jie Hu, Yan Huang, Cheng Huang, Dingzhi Huang, Wenhua Liang, Lizhu Lin, Hui Liu, Zhiyong Ma, Meiqi Shi, Yong Song, Chuanhao Tang, Jialei Wang, Lifeng Wang, Yongfeng Wang, Zhehai Wang, Nong Yang, Yu Yao, Yan Yu, Qitao Yu, Hongmei Zhang, Jun Zhao, Mingfang Zhao, Zhengfei Zhu, Xiaohui Niu, Li Zhang, Jie Wang
Publikováno v:
Journal of the National Cancer Center, Vol 3, Iss 4, Pp 256-265 (2023)
Lung cancer is the leading cause of cancer-related deaths worldwide. Bone is a common metastatic site of lung cancer, about 50% of bone metastatic patients will experience skeletal related events (SREs). SREs not only seriously impact the quality of
Externí odkaz:
https://doaj.org/article/64c371bf622d46b68856e83b202c08a9